相关实验视频
Updated: Jan 17, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.5K
[在阿托皮性皮肤炎中应用JAK抑制剂的进展]
1Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009,China.
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
|September 16, 2025
概括
两种选择性JAK抑制剂Upadacitinib和Abrocitinib为阿托皮性皮炎 (AD) 提供了新的治疗选择. 本综述详细介绍了它们的机制,试验和临床使用,强调了它们在治疗这种慢性皮肤疾病中的价值.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托匹性皮肤炎 (AD) 是一种慢性炎症性皮肤疾病,对患者造成重大负担.
- 现有的治疗方法包括局部药物,免疫抑制剂和生物药物.
- 最近的进展包括开发用于AD的小分子药物.
研究的目的:
- 审查选择性JAK抑制剂Upadacitinib和Abrocitinib在阿托皮性皮肤炎的临床应用.
- 总结它们的分子机制,临床试验数据和现实世界的临床经验.
- 突出这些药物的治疗价值在管理AD.
主要方法:
- 临床试验和研究的文献综述关于阿尔茨海默病的Upadacitinib和Abrocitinib.
- 在AD病变发生过程中,对JAK抑制的分子机制的分析.
- 关于疗效,安全性和患者结局的临床数据的综合.
主要成果:
- 乌帕达西尼布和阿布罗西尼布是选择性JAK抑制剂,已在中国批准用于AD治疗.
- 这些药物在改善AD症状和生活质量方面表现出显著的疗效.
- 临床数据支持它们在管理中度至重度亚托皮性皮肤炎方面的作用.
结论:
- 选择性JAK抑制剂代表了对亚托皮性皮肤炎的宝贵治疗进展.
- 乌帕达西提尼布和阿布罗西提尼布提供了具有明显临床特征的有效治疗选择.
- 进一步的研究和临床经验将继续改进它们在AD治疗中的使用.
相关概念视频
The JAK-STAT Signaling Pathway
12.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493

